Search results
Results from the WOW.Com Content Network
It is recommended for short-term use and is given once a month by injection into a muscle. [3] Common side effects of EC/MPA include irregular menstrual periods which typically improves with time. [3] Other side effects include blood clots, headache, hair loss, depression, nausea, and breast pain. [3] [4] Use during pregnancy is not recommended ...
Other common side effects include breast tenderness, increased facial hair, decreased scalp hair, difficulty falling or remaining asleep, stomach pain, and weight loss or gain. [24] Lowered libido has been reported as a side effect of MPA in women. [72] DMPA can affect menstrual bleeding.
Pfizer announced on Dec. 1 that it was discontinuing phase 3 clinical trials of the twice-daily version due to high rates of adverse side effects. While these were mostly mild, a large percentage ...
The side effects of cyproterone acetate (CPA), a steroidal antiandrogen and progestin, including its frequent and rare side effects, have been studied and characterized.It is generally well-tolerated and has a mild side-effect profile, regardless of dosage, when it used as a progestin or antiandrogen in combination with an estrogen such as ethinylestradiol or estradiol valerate in women.
There are side effects of weight loss injections to be aware of. Nausea and diarrhea are common with weight loss injections. Rarer (but more serious) health risks include kidney issues and ...
One of the hottest areas in the pharmaceutical sector in recent years has been weight loss, as multiple companies have been developing glucagon-like peptide 1 (GLP-1) agonist drugs, which curb a ...
Progestogen-only injectable contraceptives (POICs) are a form of hormonal contraception and progestogen-only contraception that are administered by injection and providing long-lasting birth control. [ 2 ] [ 3 ] As opposed to combined injectable contraceptives , they contain only a progestogen without an estrogen , and include two progestin ...
(Reuters) -Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, the company said on Thursday, after scrapping a twice ...